| Level 1 | Level 2 | Total | ||
---|---|---|---|---|---|
Grades 1–2 | Grade 3 | Grade 1–2 | Grade 3 | ||
Nintedanib-related event | |||||
 Diarrhea | 1/3 (33%) | 0/3 (0%) | 9/16 (56%) | 3/16 (18.8%) | 13/19 (68%) |
 Nausea | 2/3 (66.6%) | 0/3 (0%) | 9/16 (56%) | 0/16 (0%) | 11/19 (58%) |
 Vomiting | 2/3 (66.6%) | 0/3 (0%) | 9/16 (56%) | 0/16 (0%) | 11/19 (58%) |
 Asthenia | 1/3 (33%) | 1/3 (33%) | 9/16 (56%) | 0/16 (0%) | 11/19 (58%) |
 Elevated GGT | 0/3 (0%) | 0/3 (0%) | 4/16 (25%) | 4/16 (25%) | 8/19 (42%) |
 Elevated AST | 1/3 (33%) | 0/3 (0%) | 4/16 (25%) | 2/16 (12.5%) | 7/19 (36.8%) |
 Elevated ALT | 0/3 (0%) | 0/3 (0%) | 4/16 (25%) | 2/16 (12.5%) | 6/19 (31.5%) |
 Hyporexia | 0/3 (0%) | 0/3 (0%) | 3/16 (18.8%) | 0/16 (0%) | 3/19 (15.8%) |
 Dysgeusia | 1/3 (33%) | 0/3 (0%) | 2/16 (12.5%) | 0/16 (0%) | 3/19 (15.8%) |
 Hypertension | 0/3 (0%) | 0/3 (0%) | 0/16 (0%) | 2/16 (12.5%) | 2/19 (10.5%) |
 Headache | 1/3 (33%) | 0/3 (0%) | 1/16 (6.2%) | 0/16 (0%) | 2/19 (10.5%) |
Letrozole-related event | |||||
 Asthenia | 2/3 (66.6%) | 0/3 (0%) | 8/16 (50%) | 0/16 (0%) | 10/19 (52.6%) |
 Arthralgia | 1/3 (33%) | 0/3 (0%) | 7/16 (43.8%) | 0/16 (0%) | 8/19 (42%) |
 Hot flushes | 1/3 (33%) | 0/3 (0%) | 6/16 (37.5%) | 0/16 (0%) | 7/19 (36.8%) |